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Objective: In order to identify genetic variants associated with vestibular neuritis, a
common cause of peripheral vertigo with a potential causative link to the reactivation
of herpes simplex type 1 (HSV-1), we conducted a genome-wide association study.
Methods: Association was assessed using approximately 8 million variants. 131
patients with vestibular neuritis and 2,609 controls of European ancestry were included.
Results: Genome-wide associations with vestibular neuritis were detected in 4 regions
containing protein coding genes assignable to two functional groups: virus hypothesis
and insulin metabolism. Genes of set 1 are related to viral processes: nuclear receptor
subfamily 3 group C member 2 (NR3C2) is a receptor for mineralocorticoids and
glucocorticoids and was shown to be a host factor for HSV-1 replication. Ankyrin
repeat domain 30A (ANKRD30A) encodes a host factor for human immunodeficiency
virus-1 (HIV-1) infection. It shows rapid evolution and is induced by interferon stimulation.
Mediator complex 30 (MED30), an important member of the mediator complex, has
been shown to be involved in replication of HIV-1, a knockdown leading to impaired viral
replication. The second set of genes LIM homeobox transcription factor 1 alpha (LMX1A),
solute carrier family 30 member 8 (SLC30A8) is associated with insulin metabolism and
resistance, a feature of some patients in whom type 2 diabetes is an accompanying
comorbidity of vestibular neuritis.
Conclusions: Using a GWAS approach to evaluate the etiology of vestibular neuritis
these findings provide another piece of evidence that it may be caused by a viral
inflammation.
Keywords: vestibular neuritis, Herpes simplex virus type 1, genome-wide association study, virus infection, insulin
metabolism
INTRODUCTION
Evidence for a genetic background of episodic or progressive vestibular disorders is beginning
to emerge [reviewed in (1, 2)]. Common variants are revealed through genome-wide association
studies [e.g., motion sickness, (3)], and rare variants through linkage analyses followed by whole
exome sequencing (e.g., familial Meniere’s disease) (4, 5). For vestibular neuritis (VN), the third
most common cause of peripheral vestibular vertigo, evidence for heritability is very low and
linkage studies have not been published yet.
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The key symptoms of VN, also known as acute unilateral
vestibulopathy, are acute onset of sustained spinning vertigo,
oscillopsia, postural imbalance and nausea and vomiting lasting
for many days or a few weeks (6). An annual incidence of 15.5
per 100,000 persons was described (7, 8). Age of onset is typically
between 30 and 60 years (7), with an accumulation between 40
and 50 years (7, 8). Reported recurrence rates vary between 1.9%
(9) and 10.7% (10).
The most popular hypothesis of viral etiology is based
on several supporting observations, including (1) a profound
similarity of the vestibular nerve histopathology between cases of
VN and singular cases of herpes zoster oticus, (2) the deployment
of herpes simplex type 1 (HSV-1) to establish an animal model
of VN by inoculation of the virus into the auricle of mice,
(3) detection of the latency associated transcript of HSV-1 in
about 2/3 of autopsied human vestibular ganglia by PCR (11).
These findings indicate that HSV-1 resides in a latent state in
the vestibular ganglia. Reactivation of HSV-1 caused by inter-
current factors then leads to sudden replication and induction of
inflammation, edema and secondary cell damage of the vestibular
ganglion cells and axons in the bony canals [reviewed in (6)].
One of the main comorbidities in patients with VN is type 2
diabetes mellitus (T2DM) (7), which is characterized by insulin
resistance and an imbalance in glucose homoeostasis. It has been
suggested that the load of viral infection associated with chronic
low-grade inflammation might result in insulin resistance (12).
In the current approach we used a genome-wide association
study to identify genes which might be related to the disease in
order to further evaluate the etiology of VN.
SUBJECTS/MATERIALS AND METHODS
We performed a GWAS with patients with VN of European
ancestry, collected by the German Center for Vertigo and Balance
disorders (Munich, Germany), and healthy volunteers of German
descent, randomly selected from the general population of
Munich.
Patients
Patients of Caucasian descent were recruited in the German
Center for Vertigo and Balance Disorders in Munich, Germany
from 2012 to 2016. Detailed medical histories of the participants
and their first-degree relatives were assessed using a structured
interview.
Inclusion Criteria
All patients to be included had to fulfill the diagnostic criteria
for unilateral VN (6). The diagnosis was defined by the patient
history, the clinical examination and, in ambiguous cases,
laboratory examinations. Patients with recurrent VN were not
present. The inclusion criteria for this study were as follows:
Key symptoms
History of an acute/subacute onset of sustained spinning vertigo;
apparent movement of the visual surroundings (oscillopsia), gait
and postural imbalance with a tendency to fall toward the side of
the affected ear; nausea or vomiting. All symptoms had to last for
at least 72 h.
Key signs
Horizontal-rotatory peripheral vestibular spontaneous
nystagmus toward the non-affected ear, pathological head-
impulse test (HIT) toward the affected side, postural imbalance
with Romberg fall toward the affected ear.
Laboratory examinations
Caloric testing showed a hypo- or unresponsiveness of the tested
and affected horizontal canal with an >25% asymmetry between
the two sides; if the bedside head impulse was not clearly
pathological the video-HIT had to be performed with a gain of
the vestibulo-ocular reflex <0.7 on the affected side).
Exclusion Criteria
(1) Any evidence for other vestibular disorders, such as
Menière’s disease, vestibular paroxysmia, bilateral vestibulopathy,
vestibular migraine or brainstem/cerebellar infarction. (2)
History of acute hearing loss or brainstem or cerebellar
symptoms associated with these symptoms. (3) Clinical evidence
for a central lesion, i.e., skew-deviation, saccadic smooth pursuit,
gaze-evoked nystagmus, normal head-impulse test or other
central signs.
Healthy Volunteers (PAGES)
As part of the PAGES (Phenomics and Genomics Sample)
sample approximately 3,000 inhabitants from the greater Munich
area were randomly selected. Healthy unrelated volunteers of
German ancestry were included. A semi-structured interviewwas
used to assess a detailed medical, neurological and psychiatric
history of the participants, including information on their
first-degree relatives, and was followed by a comprehensive
interview including the Structured Clinical Interview for DSM-
IV (SCID I and SCID II) (13, 14), and the Family History
Assessment Module (15). CNS impairment was ruled out using
an orienting neurological examination. Subjects with a self-
reported history of VN were excluded. Finally, individuals
suffering from neurological or psychiatric diseases were excluded.
Participant Consent
Informed consent was obtained from all participants. The
study was approved by the ethics committee of the Ludwig-
Maximilians-University Munich and carried out in accordance
with the Declarations of Helsinki.
DNA Extraction
Genomic DNA was extracted from whole blood using
the QIAamp DNA Maxi Kit (Qiagen), according to the
manufacturer’s instructions and dissolved in nuclease free
water. The concentration of genomic DNA was measured using
picogreen (Molecular Probes) and adjusted to 50 ng/µl.
Genome-Wide Association Analysis
Overview
Samples were genotyped on different platforms, imputed in seven
batches and combined into one large dataset. Quality control and
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imputation of batch 1 [Human610-Quad (16), Human660W-
Quad (17)], batch 2 [HumanHap 300 (18)] and 3 [Affymetrix 6.0
(19)] were performed in the framework of a schizophrenia meta-
analysis conducted by the Psychiatric Genomics Consortium
(PGC) (20). Batches 4 [HumanHap 300 (21)], 5 [IlluminaHuman
OmniExpress 12 (22)], 6 [Illumina Omni1-Quad (23)], and
7 (HumanOmniExpress-24) were processed following quality
control and imputation protocols used by the PGC. Datasets
were combined to get a sufficient number of controls. Patients
in batch 7 were recruited for studying vertigo and balance
disorders, whereas patients of batches 1–6 were recruited for
studying psychiatric diseases, mainly schizophrenia, and thus not
included in the conducted genome-wide analysis (see Table 1).
Appropriate cases and controls were selected after global quality
control.
Quality Control of Chip Data
PLINK 1.9 (24) was used for quality control of the genotype
data. A pre-QC filtered SNV set (missingness < 0.05) was
used to exclude subjects with mismatches between reported
and estimated gender and samples with call rates below a
chip specific threshold. Sample call rate thresholds differed
slightly between chips to account for smaller sample sizes (96–
99%). After subject removal, SNV quality was assessed and
variations were excluded based on the following criteria: SNV
call rate < 99%, deviations from Hardy-Weinberg equilibrium
in controls (p ≤ 10−6) or cases (p ≤ 10−10) and SNVs with
call rate differences ≥ 0.02 between cases and controls. Also,
x-chromosomal markers with a haploid heterozygosity rate
> 2%, missingness ≥ 0.05 or HWE p ≤ 10−6 in females were
removed. A more stringent quality controlled (MAF ≥ 0.05,
HWE p ≥ 0.05, callrate ≥ 0.99) and LD-pruned autosomal
marker set was used for cryptic relatedness, heterozygosity
deviation and population stratification analyses. The marker
set was pruned with PLINK’s indep pairwise command using
r2 = 0.2, a window size of 1,500 and shifting the window 150
SNVs at each step. Additionally, several high LD regions like the
extended MHC region were excluded. One subject of each pair
with pˆi > 0.1875 was removed, cases were generally preferred
over controls. As sample contamination results in an increase
of heterozygote calls and thereby an overestimation of cryptic
TABLE 1 | Batch distribution of cases and controls.
Post-imputation GWAS
Batch N N controls N cases
1 319 0 0
2 709 262 0
3 954 925 0
4 287 99 0
5 607 578 0
6 352 267 0
7 1347 478 131
relatedness, individuals showing a heterozygosity deviation with
|Fhet| ≥ 0.2 were excluded. In addition, the quantity of pˆi
> 0.05 per individual and the distribution of pˆi means were
used to check for outliers and possible sample contamination.
Population stratification analysis was done with EIGENSTRAT
(25). SNV loadings were checked for normality and the derived
principal components were used to identify and remove outlying
samples.
Known duplicates on different chips were checked for
concordance, keeping the sample of higher quality (i.e., sample
call rate and overall chip quality). Both subjects were excluded if
the concordance rate was lower than 99%.
Pre-phasing and Imputation
Each batch was pre-phased with SHAPEIT (26) and imputed
separately on the 1,000 Genomes reference panel phase 1
version 3 macGT1 (https://mathgen.stats.ox.ac.uk/impute/
data_download_1000G_phase1_integrated.html) in chunks
of 3Mb using IMPUTE2 (27). Chr. X imputation was
performed separately for males and females. After imputation,
the seven batches were combined by retaining markers
with INFO ≥ 0.6 in every batch and the combined set.
Additionally, all markers with allele frequency differences >
0.1 between any of the batches were excluded. Checks for
cryptic relatedness, heterozygosity deviation, and population
stratification on the combined set were performed, as
described before, using the same exclusion criteria on a
stringent thresholded marker set (INFO > 0.8, missingness
< 1%, MAF > 0.05) for calling best guess genotypes with
uncertainty ≤ 0.1.
GWAS Analysis
The final mega-dataset was comprised of 4,575 individuals,
including 134VNpatients and 2,618 healthy controls appropriate
for association analysis spread across 6 batches (Table 1).
Principal components for genome-wide association analysis were
derived by EIGENSTRAT (25); 3 outlying cases and 9 controls
were removed. Tracy-Widom statistics and the scree-plot of
eigenvalues identified PC1 and PC2 as relevant (Figure 1). PC1
and PC2 were not associated with batch [Likelihood Ratio Test p
= 0.15 (PC1), p = 0.07 (PC2)]. As VN cases were typed on one
platform, controls of the six batches were used for batch effect
detection. Any marker showing deviations between any of the
batches was excluded (logistic regression corrected for PC1 and
PC2, p < 0.001). After exclusion of 116,878 variants, the final
dataset was comprised of 7,813,927 markers.
GWAS association testing of approximately 8 million variants
(INFO ≥ 0.6, MAF ≥ 0.01 in cases and controls) using 131
patients with VN and 2,609 healthy subjects was conducted in
PLINK 1.9 (24) applying an additive logistic regression model
corrected for age, sex, PC1 and PC2. Quantile-quantile and
Manhattan plots are shown (Figures 2, 3). The genomic inflation
factor was 1, thus showing no sign of global inflation due to batch
effects or population stratification. Results were clumped with
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FIGURE 1 | (A) Scatterplot of the first two principal components derived by
EIGENSTRAT. (B) Scree-plot of principal components 1–20 derived by
EIGENSTRAT.
PLINK to derive LD independent index SNVs (3,000 kb, p1 = 5
× 10−8, p2= 1× 10−4, r2 < 0.1).
RESULTS
One-hundred and thirty-one patients with VN (64 females,
51%) and 2609 healthy subjects (1402 females, 54%) were
examined. The mean age (± SD) of the patients was 58.02
± 13.6 years, mean age of controls was 47.41 ± 16.6 years.
Among approximately 8 million variants tested for association
we identified 9 genome-wide associated SNVs (p < 5 × 10−8)
mapping to four independent loci. Hits on chromosomes 1 and
10 showed isolated signals and should therefore be interpreted
with caution. Themost promising association signal was found in
the chromosome 4 region (leading SNV rs186544372) (Figures 2,
3, Table 2).
The most significant SNV rs74835610 (p = 5.54 × 10−11)
in this study was localized on chromosome 1q23.3 app. 30 kb
downstream to LIM homeobox transcription factor 1 alpha
(LMX1A), a gene coding for a transcription factor, involved
in the regulation of insulin gene transcription (28) as well as
in the development of dopamine producing neurons during
embryogenesis (29) (Figure 4A).
Next in line was rs188172955 (p = 1.46 × 10−9) on
chromosome 10p11.21 which is localized 78 kb distant to
the ankyrin repeat domain 30A gene (ANKRD30A, NY-BR-
1), a DNA-binding transcription factor primarily expressed
in mammary epithelium and testis (30) (Figure 4B). The
region on chromosome 4q31.23, represented by the index SNV
rs186544372 (p = 1.54 × 10−9) contains 7 additional genome-
wide associated SNVs, with 5 localized in the predicted long non-
coding RNA (ncRNA) LOC107986195, spanning app. 500 kb
(rs138007517, p = 8.14 × 10−9; rs139369934, p = 8,23 × 10−9;
rs115679368, p = 1.10 × 10−8; rs186151434, p = 1.18 × 10−8;
rs140247570, p = 2.34 × 10−8) and an additional 2 localized in
the long intergenic non-protein coding RNA 2355 (rs182341058,
p= 4.65× 10−8, rs187446780, p= 4.73× 10−8). The next coding
gene, nuclear receptor subfamily 3 group C member 2 (NR3C2),
is app. 400 kb distant and codes for the mineralocorticoid
receptor (MC-R), which is activated by mineralocorticoids such
as aldosterone, thereby influencing the salt and water balance
within a variety of target cells (31) (Figure 4C).
The region on chromosome 8q24.11 with the index SNV
rs1499428 (p = 3.72 × 10−8) is localized in an intronic region of
2 overlapping ncRNAs (LOC105375717, LOC105375716), 111 kb
downstream of solute carrier family 30 member 8 (SLC30A8)
and also 232 kb upstream of mediator complex 30 (MED30)
(Figure 4D). SLC30A8 encodes the zinc eﬄux transporter ZnT8
which is involved in the accumulation of zinc in intracellular
vesicles, MED30 is part of the mediator complex, a multiprotein
complex required for gene transcription by RNA polymerase II
(32).
None of the significant associated variants could be directly
assigned to a protein coding gene. The minimal distance to the
nearest gene was app. 30 kb (LMX1A, rs74835610), maximum
distance app. 400 kb (NR3C2, rs186544372).
DISCUSSION
In this study a genome-wide association with VN was found for
four regions. The next protein coding genes in those regions
can be divided into two functionally different groups: virus
hypothesis and insulin metabolism.
The first group contains three hits on chromosomes 4q31.23
(NR3C2), 8q24.11 (MED30), and 10p11.21 (ANKRD30A) that
show a connection to the virus hypothesis. Two hits are localized
in predicted ncRNAs, linking the adjacent genes NR3C2 (host
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FIGURE 2 | Manhattan plot of the genome-wide association analysis of 131 cases and 2,609 controls. The x-axis shows the chromosomal position, the y-axis the
significance of association [–log10(p)]. The red line shows the genome-wide significance level (5 × 10
−8). Genomic variations in orange are in LD (r2 > 0.6, p =
0.0001) with the index SNVs (diamonds) which represent independent genome-wide significant associations (r2 < 0.1).
FIGURE 3 | Quantile-quantile plot of GWAS analysis. The area shaded in gray
indicates the 95% confidence interval under the null.
factor for HSV-1) and MED30 (HIV-1 replication) to VN,
the third hit is localized near ANKRD30A (host factor for
HIV-1).
The second group consists of LMX1A (1q23.3) and SLC30A8
(8q24.11), which are involved in insulin metabolism.
Group 1: Virus Hypothesis
The predicted long ncRNA (LOC107986195) on chromosome
4q31.23 provides a physical link to NR3C2, encoding the
mineralocorticoid receptor (MC-R) which together with
mineralcorticoids regulates ion-homeostasis mainly in epithelial
cells. In addition to acting as a ligand-dependent transcription
factor which by binding to mineralocorticoid response elements
leads to a late response following the transactivation of specific
target genes, MC-R seems to directly transactivate unrelated
receptors, thereby influencing intracellular signaling pathways
more rapidly (33).
Also, NR3C2 was shown to be a host factor for HSV-1
replication. After knock down via siRNA depletion, NR3C2
specifically enhanced HSV-1 replication (34). Furthermore,
using a murine model of HSV-1 infection a role of the
MC-R in the neuroendocrine-mediated modulation of
antiviral immunity has been discussed (35). For stress-
induced glucocorticoids a strong suppression of CD8+ T
cell immune responses could be demonstrated, leading
to diminished antiviral immunity (36). This together
with the implication of an intricate interdependence of
glucocorticoid receptors (GC-R) and MC-R functions
points toward a participation of both in antiviral immune
response.
Apart from mineralocorticoids, the human MC-R has a high
affinity for glucocorticoids which, in the form of synthetic
glucocorticoids like methylprednisolone, are used in the therapy
of vestibular neuritis as well as other vertigo diseases (37, 38).
The therapeutic effect of glucocorticoid application seems to
be dependent not only on tissue type and local concentration
but also on a concerted action of GC-R and MC-R on
transcriptionally and non-transcriptionally mediated signaling
pathways (39).
Another hit is localized on chromosome 8q24.11 in the
intronic regions of two overlapping ncRNAs (LOC105375717,
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TABLE 2 | Genome-wide association of 4 regions with vestibular neuritis.
Chr. (region) SNV A1 Info Frqcontrol Frqcase OR (95% CI) P-value Gene (dist.)
chr. 01
(165140414)
rs74835610 T 0.799 0.985 0.931 0.134
(0.073–0.245)
7.54E−11 LMX1A
(30690)
chr. 10
(37286040–37406937)
rs188172955 A 0.900 0.017 0.077 5,697
(3.242–10.013)
1.46E−9 ANKRD30A
(78196)
chr. 04
(149770763–
150153801)
rs186544372 A 0.863 0.015 0.068 6,356
(3.488–11.583)
1.54E−9 NR3C2
(404324–578878)
rs138007517 A 0.899 0.984 0.932 0,178
(0.099–0.320)
8.14E−9
rs139369934 T 0.898 0.016 0.068 5,605
(3.119–10.070)
8.23E−9
rs115679368 A 0.910 0.984 0.932 0,183
(0.102–0.327)
1.10E−8
rs186151434 C 0.912 0.984 0.932 0.184
(0.103–0.329)
1.18E−8
rs140247570 C 0.906 0.016 0.068 5.239
(2.930–9.370)
2.34E−8
rs182341058 T 0.888 0.014 0.061 5.643
(3.034–10.498)
4.65E−8
rs187446780 T 0.888 0.986 0.940 0.177
(0.095–0.330)
4.73E−8
chr. 08
(118300175–
118301384)
rs1499428 C 0.845 0.862 0.749 0.402
(0.290–0.556)
3.72E−8 SLC30A8
(111222)
MED30
(232790)
SNV associations are sorted by P-value. Chromosome and position denote the associated region surrounding the index SNV (in bold) containing 1 or more variation in LD (r2 > 0.6)
with the index SNV. A1, reference allele; Frq, allele frequency; OR, odds ratio; CI, confidence interval; gene, next protein coding gene; dist., distance to index SNV in bp.
LOC105375716), thereby providing a link to the neighboring
genes SLC30A8 and MED30.
MED30 is part of the tail of the mediator complex, a
multiprotein complex required for gene transcription by RNA
polymerase II, thereby controlling the expression of genes
through subunit specific interaction, epigenetic regulation,
elongation and termination of transcription, processing of
mRNA, activation of noncoding RNA as well as formation of
super enhancers (32). MED30 has been shown to be involved
in replication of HIV-1, a knockdown leading to impaired viral
replication (40). Although not directly linked to HSV-1 itself,
several other genes of the mediator complex have been shown
to be host factors for HSV-1 infection. For example, MED23
has been shown to conduct a HSV-1 specific anti-viral effect.
Interaction of the transcription factor IRF7 withMED23 induced
an upregulated expression of the interferon lambda family.
Interferon lambda, on the other hand, has been suggested to
play a crucial role in HSV-1 immune control (34). Also, Tat-
mediated transcription was impaired after RNAi knockdown
(41). Functional roles of MED30 are poorly understood. It was
found to play a fundamental role in the regulation of function
and integrity ofmitochondria inmice homozygous for amissense
mutation (42).
The variants attributed to MED30 and NR3C2 are localized in
predicted ncRNAs with unknown function, but involvement in
antiviral host response has recently been shown for this type of
RNA (43). Therefore, it could be hypothesized that the associated
ncRNAs exert a potentially regulatory influence on the adjacent
genes.
Another link to virus response is provided by a hit on
chromosome 10p11.21, next to the ANKRD30A/NY-BR-1 gene.
Though mostly known as an antigen associated with breast
cancer progression (30), this gene was also determined to be
an HIV-1 host susceptibility factor using whole-genome RNA
interference screens (41), and shows a strong signature of
positive virus-driven selection in an evolutionary analysis (44).
Further work is necessary to characterize the role of ANKRD30A
regarding its involvement in HIV-1 biology, especially as
ANKRD30A has been shown to be one of very few candidates
with potential as a drug target (45).
Group 2: Insulin Metabolism
The most significant SNV rs74835610 is localized 30 kb from
the transcription factor LMX1A. LMX1A and LMX1B play
an essential role during the development of dopaminergic
progenitors in the midbrain. In a mouse model Lmx1a was
shown to be essential for the conversion of non-neuronal
floor-plate cells into neuronal dopamine progenitors (29).
Lmx1a-deficiency in mice reduced Tph1 expression, the
rate-limiting enzyme for serotonin biosynthesis (46). In
addition to its role in the development of dopamine
producing neurons during embryogenesis (29) and
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FIGURE 4 | Regional association plots for the four novel vestibular neuritis loci. In order to highlight the statistical strength of the association in the context of the
surrounding markers, gene annotations and estimated recombination rates (NCBI build 37) of the SNVs in the specific regions are plotted against their corresponding
P-values (as –log10 values, left-hand y-axis). A purple diamond represents the SNV with the highest association signal in each locus. All other variations are
represented as single dots, where dot colors indicate the LD with the associated SNV. Color coding represents the r2 value and respective categories are shown on
the upper left hand side. Estimated recombination rates (cM/Mb) are plotted to reflect the local LD structure surrounding the associated SNV and are shown as
vertical light blue lines, marked on the right-hand y-axis. Genes in the region are displayed below. Orientation of the genes is indicated by arrows. (A) LMX1A. Regional
association plot of rs74835610 on chromosome 1q23.3. This genome-wide associated SNV (purple diamond) is localized 30 kb from LIM homeobox transcription
factor 1 alpha (LMX1A). No additional variations in high LD or with low P-Values are present in this region. (B) ANKRD30A. Regional association plot of rs188172955
on chromosome 10p11.21. This genome-wide associated SNV (purple diamond) is localized 78 kb from ankyrin repeat domain 30A (ANKRD30A). Additional variations
in LD (r2 between 0.2 and 0.8) surround this SNV but fail to reach genome-wide significance. (C) NR3C2. Regional association plot of rs186544372 on chromosome
4q31.23. The most significant SNV in this region as well as five other genome-wide associated SNVs in high LD (r2 > 0.8, red dots) are localized on a predicted long
ncRNA (LOC107986195). The next coding gene, nuclear receptor subfamily 3 group C member 2 gene (NR3C2) is localized in 100 kb distance. (D) SLC30A8/MED30.
Regional association plot of rs1499428 on chromosome 8q24.11. This genome-wide associated SNV (purple diamond) is localized in the intronic regions of two
overlapping ncRNAs (LOC105375717, LOC105375716). The next coding genes are solute carrier family 30 member 8 (SLC30A8) and mediator complex 30 (MED30).
serotonin biosynthesis (46), Lmx1A also seems to have a
role in the positive regulation of insulin gene transcription
(28).
The associated variation localized on 8q24.11 could be
attributed to MED30 as well as to SLC30A8. The human
SLC30 gene family of solute carriers seems to be involved
in the maintenance of zinc homeostasis and in facilitation of
zinc transport from the cytoplasm into specialized intracellular
compartments or the extracellular space (47). SLC30A8 encodes
the zinc eﬄux transporter ZnT8 which affects the accumulation
of zinc in intracellular vesicles and shows high expression levels
in the islets of Langerhans cells of the pancreas. Zinc is required
for zinc-insulin crystallization in the immature granules of these
cells. By stimulating these cells with glucose, large amounts of the
mature granules are secreted to the extracellular space, thereby
delivering zinc together with insulin. It has been suggested that
zinc plays a role in the paracrine and/or autocrine signaling
mechanisms in islet cells (48). Loss-of-function mutations in
SLC30A8 seems to be strongly protective against type 2 diabetes
(49).
In summary, we identified four regions attributable to five
genes, three of which (NR3C2, ANKRD30A, MED30) are
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involved in viral processes: NR3C2 was shown to be a host
factor for HSV-1 replication, ANKRD30A is a host factor for
HIV-1 infection and MED30 has been shown to be involved in
replication of HIV-1.
The second set of genes comprising LMX1A and SLC30A8
is involved in insulin metabolism and might be relevant for
the frequently occurring metabolic comorbidities like T2DM,
supporting the hypothesis of susceptibility to insulin resistance
as a consequence of an increased exposure to pathogens leading
to chronic low-grade inflammation.
Though the number of VN cases is very small for a GWAS
analysis, and the isolated association signals on chromosomes
1 and 10 should be considered with caution, these findings—
in addition to other studies using different methods—provide
preliminary support for the view that viral inflammation is a
causative factor in the etiology of VN.
LIMITATIONS
The study is limited by the small sample size and the fact that
individuals were genotyped on several platforms. Minor allele
frequencies of genome-wide significant markers are in general
low and larger sample sizes and independent replications are
required to explore the causative factors of VN.
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